News

Close-up of the arms of scientist in white lab coat wearing blue gloves and holding an injection device.

Moderna's mRNA vaccines take on cancer

New York Times

Moderna, co-founded by Bob Langer, announced that late-stage trials showed its mRNA cancer vaccine reduced the ​risk of melanoma recurrence and spread when used in conjunction with an immunotherapy called pembrolizumab—the first positive results for mRNA cancer vaccines and for combination therapies with pembrolizumab. Moderna is testing similar approaches against lung, breast, and pancreatic cancers with its partners.

New York Times | Washington Post | STAT | CNBC

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Douglas Lauffenburger named Institute Professor

MIT News

Three cheers to Douglas Lauffenburger, one of a trio of MIT faculty members named Institute Professors this year. Lauffenburger receives MIT’s highest honor for his contributions as the founding head of the Department of Biological Engineering and key roles in launching interdisciplinary programs, as well as his work developing predictive models of molecular and cellular networks.

Remembering Susumu Tonegawa 

MIT News

The Koch Institute joins the MIT community in mourning Nobel Laureate Susumu Tonegawa, an alumnus of the MIT Center for Cancer Research (our predecessor) and founding director of the Picower Institute for Learning and Memory. Driven by curiosity about fundamental questions in biology, Tonegawa made groundbreaking discoveries in immunology and neuroscience. Awarded the 1987 Nobel Prize in Physiology or Medicine for uncovering the genetic basis of antibody diversity, he later transformed our understanding of how memories are formed, stored, and recalled.

PRMT5 inhibitors in Merkel cell carcinoma

Nature Communications Biology

A Nature Communications Biology study published by Bridge Project collaborators Jacqueline Lees (Koch InstituteI) and James DeCaprio  (Dana-Farber Cancer Institute) uncovers previously unknown mechanisms underlying the sensitivity of Merkel cell carcinoma, a rare and aggressive neuroendocrine skin cancer, to PRMT5 inhibitors. They found that PRMT5 inhibitor sensitivity is not dependent on the activation of tumor-suppressor gene p53, as previously believed. They further showed that PRMT5 inhibition disrupts intron splicing and impairs ATR signaling with increased DNA damage, which may point the way to improving the efficacy of PRMT5 inhibitors and help clinicians identify patients who are more likely to respond to these therapies.

Equipped for the future

Massachusetts LIfe Sciences Center

Massachusett’s Healey-Driscoll Administration announced more than $19.7 million in funding supporting the life sciences for 23 projects that will expand cutting-edge research infrastructure, accelerate artificial intelligence and data science, advance next-generation therapeutic delivery technologies, and help move promising discoveries closer to patients. The KI’s Integrated Tissue Processing and Spatial Imaging Core Facility will receive a research equipment grant, which will support a shared, high-throughput auto-stainer.  

Sangeeta Bhatia, then and now

The Scientist

In celebration of their 40th anniversary, The Scientist catches up with Sangeeta Bhatia since her profiles in 2006 and  2013, giving her an opportunity to reflect on her journey in pioneering liver research, developing advanced diagnostics, and launching multiple companies. She emphasizes that she never expected her career to take this path: “We're all so focused on being strategic and planning our journey, and the truth of the matter is that the field I ended up in didn't exist on the day I graduated. The best things that happen are surprises.”

Future Health joins BioConvergence Cancer Alliance as founding member

Future Health Initiatives

The BioConvergence Cancer Alliance at MIT’s Koch Institute is expanding its global network with the addition of a founding member: Future Health – A Global Initiative by Abu Dhabi.The partnership will create new opportunities for collaboration across research, healthcare, and industry, advancing efforts in cancer prevention, earlier detection, and more effective treatments  

Sound thinking

MIT News

KI alum Canan Dagdeviren and colleagues have developed a portable ultrasound system, described in Nature Communications, that could make reliable breast imaging more accessible. Dagdeviren was also named one of four winners of the 2026 Nature Awards Healthspan Accelerator, which recognizes research with the potential to transform human healthspan.

Whitney Henry named 2026 Pew Scholar

MIT News

Congratulations to Koch Institute faculty member Whitney Henry on being named a 2026 Pew Scholar in the Biomedical Sciences. The prestigious program supports early-career investigators with four years of flexible funding to pursue innovative research. Henry studies ferroptosis in cell fate and tissue remodeling, with implications for disease and regeneration.

Matthew Vander Heiden named Editor-in-Chief of AACR’s Cancer Discovery

American Association for Cancer Research

Congratulations to KI Director Matthew Vander Heiden on his appointment as Editor-in-Chief of Cancer Discovery, the American Association for Cancer Research's flagship journal and one of the world's leading cancer research publications. In this leadership role, he will help shape the publication of impactful research spanning basic, translational, and clinical cancer science.

A dynaMIT summer of discovery

MIT News

This summer, the Koch Institute is partnering with MIT’s student-run dynaMIT program to bring hands-on cancer research experiences to local middle school students. Through lab tours, interactive experiments, and conversations with scientists, students will get an inside look at the exciting work happening at the Koch Institute.